Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy

Abstract

Olopatadine topical ophthalmic solution is a potent antiallergic agent that has selective histamine H₁-receptor antagonizing and mast cell-stabilizing activity. Olopatadine is available as a 0.1% formulation and, more recently, as a 0.2% formulation. The drug inhibits proinflammatory mast cell mediator release, specifically histamine, and the release of inflammatory lipid mediators such as leukotriene and thromboxane from human leukocytes and eosinophils. In preclinical and clinical studies, olopatadine has proven to be a safe, comfortable and effective medication for the treatment of seasonal and perennial allergic conjunctivitis. The drug effectively relieves itching, redness, chemosis, tearing and lid swelling related to ocular allergy, and is also helpful in the management of nasal allergic symptoms. This article will review the current literature on the safety and efficacy of olopatadine, and will discuss the role of olopatadine in treating ocular allergy.

Keywords::

• allergic conjunctivitis
• antihistamines
• mast cell stabilizers
• ocular allergy
• olopatadine

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.